Ellie (eleanor) Barnes BSc. MBBS. PhD, FRCP. FMedSci.

Professor Eleanor Barnes FMedSci was lead an established research group with a focus on applied immunology relevant to liver disease, including cancer, and Barnes seek to translate laboratory and clinical findings through to human experimental medicine studies.

Eleanor Barnes group is developing T cell pan-genotypic vaccines for hepatitis C virus (HCV) prevention and hepatitis B virus (HBV) cure using simian adenoviral and other viral vectors. We are also assessing COVID vaccines in disease cohorts. A major challenge for HCV vaccine development is the significant viral diversity both within the same host and between hosts – though parts of the viral genome are conserved, making these excellent T cell targets in the context of a T cell vaccine. Some of the technologies we are developing include integral genetic adjuvants that will have applicability in a broad range of diseases.